tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

HALO Stock Latest News

Strategic Acquisition and FDA Approval Bolster Halozyme’s Market Position with a Buy Rating
RatingsStrategic Acquisition and FDA Approval Bolster Halozyme’s Market Position with a Buy Rating
5d ago
HALO
Halozyme Announces CFO Transition Plan
PremiumCompany Announcements
Halozyme Announces CFO Transition Plan
9d ago
8K
HALO
Strategic Importance of Halozyme’s ENHANZE Platform and Its Growth Potential in Subcutaneous Drug Delivery
PremiumRatings
Strategic Importance of Halozyme’s ENHANZE Platform and Its Growth Potential in Subcutaneous Drug Delivery
14d ago
HALO
Halozyme price target raised to $56 from $54 at Goldman Sachs
PremiumThe Fly
Halozyme price target raised to $56 from $54 at Goldman Sachs
15d ago
HALO
Merus, Halozyme enter collaboration, license agreement for petosemtamab
PremiumThe Fly
Merus, Halozyme enter collaboration, license agreement for petosemtamab
16d ago
HALO
MRUS
Halozyme Completes $1.5 Billion Convertible Notes Sale
PremiumCompany AnnouncementsHalozyme Completes $1.5 Billion Convertible Notes Sale
21d ago
8K
HALO
Halozyme: JNJ gets FDA approval for new indication of DARZALEX Faspro
Premium
The Fly
Halozyme: JNJ gets FDA approval for new indication of DARZALEX Faspro
26d ago
JNJ
HALO
Halozyme Announces Pricing of $1.3 Billion in Notes
Premium
Company Announcements
Halozyme Announces Pricing of $1.3 Billion in Notes
26d ago
8K
HALO
Halozyme Extends Credit Facility and Increases Commitments
PremiumCompany Announcements
Halozyme Extends Credit Facility and Increases Commitments
28d ago
8K
HALO
Halozyme announces two offerings totalling $1.3B in convertible senior notes
PremiumThe Fly
Halozyme announces two offerings totalling $1.3B in convertible senior notes
28d ago
HALO
Halozyme Therapeutics’ Earnings Call Highlights Robust Growth
PremiumCompany Announcements
Halozyme Therapeutics’ Earnings Call Highlights Robust Growth
29d ago
HALO
Halozyme price target raised to $92 from $91 at Citizens JMP
PremiumThe Fly
Halozyme price target raised to $92 from $91 at Citizens JMP
29d ago
HALO
Halozyme Therapeutics Reports Strong Q3 2025 Results
PremiumCompany AnnouncementsHalozyme Therapeutics Reports Strong Q3 2025 Results
30d ago
HALO
Halozyme’s Strong Q3 Performance and Promising Future Drive Buy Rating
Premium
Ratings
Halozyme’s Strong Q3 Performance and Promising Future Drive Buy Rating
30d ago
HALO
Halozyme Raises 2025 Guidance After Strong Q3 Results
Premium
Company Announcements
Halozyme Raises 2025 Guidance After Strong Q3 Results
30d ago
8K
HALO
Halozyme raises 2025 non-GAAP EPS view to $6.10-$6.50 from $6.00-$6.40
PremiumThe Fly
Halozyme raises 2025 non-GAAP EPS view to $6.10-$6.50 from $6.00-$6.40
30d ago
HALO
Halozyme reports Q3 non-GAAP EPS $1.72, consensus $1.61
PremiumThe Fly
Halozyme reports Q3 non-GAAP EPS $1.72, consensus $1.61
30d ago
HALO
Is HALO a Buy, Before Earnings?
PremiumPre-Earnings
Is HALO a Buy, Before Earnings?
1M ago
HALO
Halozyme price target raised to $65 from $63 at JPMorgan
PremiumThe Fly
Halozyme price target raised to $65 from $63 at JPMorgan
1M ago
HALO
Buy Rating for Halozyme: Strong Growth Prospects Backed by Successful MajesTEC-3 Trial and Robust Financial Valuation
PremiumRatingsBuy Rating for Halozyme: Strong Growth Prospects Backed by Successful MajesTEC-3 Trial and Robust Financial Valuation
1M ago
HALO
Halozyme price target lowered to $79 from $80 at Morgan Stanley
Premium
The Fly
Halozyme price target lowered to $79 from $80 at Morgan Stanley
1M ago
HALO
Halozyme’s Strong Royalty Revenue and Strategic Initiatives Justify Buy Rating Despite Potential Risks
Premium
Ratings
Halozyme’s Strong Royalty Revenue and Strategic Initiatives Justify Buy Rating Despite Potential Risks
1M ago
HALO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >